

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known			
		Application Number	Continuation of 09/316,226		
		Filing Date	October 26, 2000		
		First Named Inventor	M. Rigdon Lentz		
		Group Art Unit			
Examiner Name					
Sheet	1	of	3	Attorney Docket Number	LEN 101 CIP CON

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	US Patent Document		Name of Patentee or Applicant of Cited Document	Date of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
QUB		4,708,713	✓	Lentz	11-24-1987	
		4,486,282	✓	Bier	12-04-1984	
		5,135,919	✓	Folkman, et al.	08-04-1992	
		5,147,638	✓	Esmon, et al.	09-15-1992	
		5,290,807	✓	Folkman, et al.	03-01-1994	
		5,523,096	✓	Okarma, et al.	06-04-1996	
		5,629,327	✓	D'Amato	05-13-1997	
		5,639,725	✓	O'Reilly, et al.	06-17-1997	
		5,679,260	✓	Boos, et al.	10-21-1997	
		5,698,586	✓	Kishimoto, et al.	12-16-1997	
		5,712,291	✓	D'Amato	01-27-1998	
		5,713,491	✓	Hughes, et al.	02-03-1998	
		5,716,981	✓	Hunter, et al.	02-10-1998	
		5,733,876	✓	O'Reilly, et al.	03-31-1998	
		5,861,483	✓	Wolpe	01-19-1999	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office. ³	Number ⁴	Kind Code ⁵ (if known)				
QUB		DE	43 45 200	A1	Fresenius AG	12-22-1994		
QUB		DE	196 24 250	A1	Ahrenholz, et al.	01-02-1998		

Examine Signature	<i>JBianco</i>	Date Considered	10 October 2002
-------------------	----------------	-----------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commissioner for Patent, Washington, DC 20231.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	Continuation of 09/316,226
		Filing Date	October 26, 2000
		First Named Inventor	M. Rigdon Lentz
		Group Art Unit	
		Examiner Name	
Sheet 2 of 3	Attorney Docket Number	LEN 101 CIP CON	

107-267-88
109/699003
JCS27 U.S. PRO

OTHER ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
RB	✓	*ANDREWS, et al., "Characterization of the receptor for tumor necrosis factor (TNF) and lymphotoxin LT) on human T lymphocytes: TNF and LT differ in their receptor binding properties and the induction of MHC class I proteins on a human CD4 ⁺ T cell hybridoma," <i>J Immunol</i> 144(7):2582-91 (1990).	
↓	✓	*BONAVIDA, et al., (eds), Tumor Necrosis Factor/Cachecin and Related Cytokines. Int. Conf. Tumor Necrosis Factor and Related Cytotoxins, Heidelberg, 1987, pp. 7-19 (Karger, Basel 1988).	
RB	✓	CHEN, et al., "Soluble TNF- Receptors are constitutively shed and downregulate adhesion molecule expression in malignant gliomas," <i>J. Neuropathol. Exp. Neurol.</i> 56(5):541-550 (1997).	
		COLMAN, et al., Hemostasis and Thrombosis: Basic Principles and Clinical Practice (2nd Ed.), p. 263, J.B. Lippincott: Philadelphia, PA, 1987.	
RB	✓	*FEINMAN, et al., "Tumor necrosis factor is a important mediator of tumor cell killing by human monocytes," <i>J Immunol</i> 138(2):635-40 (1987).	
↓	✓	*GATANAGA, et al., "Identification of TNF-LT blocking factor(s) in the serum and ultrafiltrates of human cancer patients," <i>Lymphokine Res</i> 9(2):225-29 (1990).	
↓	✓	*HARANAKA & SATOMI, "Cytotoxic activity of tumor necrosis factor (TNF) on human cancer cells <i>in vitro</i> ," <i>Jpn J Exp Med</i> 51(3):191-94 (1981).	
RB	✓	*HOWARD, et al., Vaccinia virus homologues of the Shope fibroma virus inverted terminal repeat proteins and a discontinuous ORF related to the tumor necrosis factor receptor family," <i>Virology</i> 180(2):633-47 (1991).	
		JABLONSKA & PEETRUSKA, "Release of soluble tumor necrosis factor receptors from polymorphonuclear cells of breast cancer patients," <i>Arch Immunol Ther Exp (Warsz)</i>, 45(5-6):449-53 (1997).	
RB	✓	*LANGKOPF & ATZPODIEN, "Soluble tumor necrosis factor receptors as prognostic factors in cancer patients," <i>Lancet</i> 344(8914):57-58 (1994).	

Examiner's Signature	<i>R. Bianco</i>	Date Considered	10 October 2002
----------------------	------------------	-----------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known			
		Application Number	Continuation of 09/316,226		
		Filing Date	October 26, 2000		
		First Named Inventor	M. Rigdon Lentz		
		Group Art Unit			
		Examiner Name			
Sheet	3	of	3	Attorney Docket Number	LEN 101 CIP CON

 J5927 U.S. PTO
 09/26/00


OTHER ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
AB	✓	*MATHIAS, et al., "Activation of the Sphingomyelin signaling pathway intact EL4 cells and in a cell-free system by IL-1," <i>Science</i> 259:519-22 (1993).	
		MATSCHNER, et al., <i>Current Advances in Vitamin K Research</i>, pp. 135-140, (John W. Suttie, ed.) Elsevier Science Publishing Co., Inc., 1988.	
EB	✓	*PHILIP & EPSTEIN, "Tumor necrosis factor as immunomodulator and mediator of monocyte cytotoxicity induced by itself, Gamma-interferon and Interleukin-1," <i>Nature</i> 323(6083):86-87 (1986).	
↓	✓	*URBAN, et al., "Tumor necrosis factor: A potent effector molecule for tumor cell killing by activated macrophages," <i>Proc Natl Acad Sci USA</i> 83:5233-37 (1986).	
UB	✓	*ZIEGLER-HEITBROCK, et al., "Tumor necrosis factor as effector molecule in monocyte-mediated cytotoxicity," <i>Cancer Res</i> 46:5947-52 (1986).	

Examiner's Signature	<i>AB Bianco</i>	Date Considered	10 October 2002
----------------------	------------------	-----------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



COPIES MADE
ORIGINALLY FILED

PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

+

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known

(use as many sheets as necessary)

09/699.003

October 26, 2000

M. Rigdon Lentz

3762

--	--

LEN 101 CIP CON

1

of

2

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]

Subaru

10 October 2002

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO:** Assistant Commission for Patent, Washington, DC 20231.

ATL1 #505411 v1

LEN 101 CIP CON
077829-00009

COPY OF PATENT'S
ORIGINALLY FILED

Please type a plus sign (+) inside this box →



PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number



Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Complete if Known

Application Number	09/699,003
Filing Date	October 26, 2000
First Named Inventor	M. Rigdon Lentz
Group Art Unit	3762
Examiner Name	
Attorney Docket Number	LEN 101 CIP CON

Sheet 2 of 2

OTHER ART - NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
Sub	✓	GATANAGA, et al., "Purification and characterization of an inhibitor (soluble tumor necrosis factor receptor) for tumor necrosis factor and lymphotoxin obtained from the serum ultrafiltrates of human cancer patients," <i>Proceedings of the National Academy of the USA</i> 87(22):8781-87814 (1990).	
Sub	✓	LENTZ, "Continuous whole blood UltraPheresis procedure in patients with metastatic cancer," <i>Journal of Biological Response Modifiers</i> 8(5):511-527 (1989).	
Sub	✓	LENTZ, "The role of therapeutic apheresis in the treatment of cancer: a review," <i>Therapeutic Apheresis</i> 3(1):40-49 (1999).	
Sub	✓	SELINSKY, et al., "Multifaceted inhibition of anti-tumor immune mechanisms by soluble tumour necrosis factor receptor type-1," <i>Immunology</i> 94(1):88-93 (1998).	
Sub	✓	TETTA, et al., "Continuous plasma filtration coupled with sorbents," <i>Kidney International</i> 53(66):S186-S189 (1998).	

RECEIVED
MAY - 6 2002
TO 3762 MAIL ROOM

Examiner's Signature	<i>Sub</i>	Date Considered	10 October 2002
----------------------	------------	-----------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.